Skip to main content
[Preprint]. 2023 Jul 17:rs.3.rs-3112163. [Version 1] doi: 10.21203/rs.3.rs-3112163/v1

Table 3.

Best overall response to therapy.

Vactosertib and Pomalidomide
Response N (%)
 Partial response 4 (21%)
 Minimal/Marginal response 2 (11%)
 Stable disease 9 (47%)
 Progressive disease 4 (21%)
 Not evaluable 2 (11%)
Overall Response Rate
(Partial + Minimal)
6 (32%)
Clinical Benefit Ratio (CBR)
(Stable disease + Partial + Minimal)
15 (69%)

Data are n (%), unless stated otherwise. Overall response to treatment (secondary endpoint) was derived according to IMWG criteria.